Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 146888 89 0?
Displaying drugs 526 - 550 of 1437 in total
Investigational
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
Investigational
Investigational
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Investigational
Investigational
Brogidirsen is under investigation in clinical trial NCT05996003 (NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)).
Investigational
Investigational
Investigational
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Investigational
Investigational
Experimental
Withdrawn
Experimental
Withdrawn
BIIB021 has been investigated for the treatment of Tumors and Lymphoma.
Investigational
Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).
Investigational
Investigational
Investigational
U-0126 is a direct inhibitor of the mitogen-activated protein-kinase kinase family members, MEK-1 and MEK-2.
Investigational
Investigational
ALMB-0168 is a humanized connexin 43 (Cx43) monoclonal antibody being investigated for osteosarcoma.
Investigational
MBP-091 is a monoclonal antibody being investigated for the treatment of Marburg virus disease (MVD) caused by infection with Marburg virus (MARV).
Investigational
Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).
Investigational
Displaying drugs 526 - 550 of 1437 in total